TY - JOUR
T1 - Targeting USP7 identifies a metastasis-competent state within bone marrow–resident melanoma CTCs
AU - Vishnoi, Monika
AU - Boral, Debasish
AU - Liu, Haowen
AU - Sprouse, Marc L.
AU - Yin, Wei
AU - Goswami-Sewell, Debalina
AU - Tetzlaff, Michael T.
AU - Davies, Michael A.
AU - Glitza Oliva, Isabella C.
AU - Marchetti, Dario
N1 - ©2018 American Association for Cancer Research.
PY - 2018/9/15
Y1 - 2018/9/15
N2 - Systemic metastasis is the major cause of death from melanoma, the most lethal form of skin cancer. Although most patients with melanoma exhibit a substantial gap between onset of primary and metastatic tumors, signaling mechanisms implicated in the period of metastatic latency remain unclear. We hypothesized that melanoma circulating tumor cells (CTC) home to and reside in the bone marrow during the asymptomatic phase of disease progression. Using a strategy to deplete normal cell lineages (Lin
-), we isolated CTC-enriched cell populations from the blood of patients with metastatic melanoma, verified by the presence of putative CTCs characterized by melanoma-specific biomarkers and upregulated gene transcripts involved in cell survival and prodevelopment functions. Implantation of Lin
- population in NSG mice (CTC-derived xenografts, i.e., CDX), and subsequent transcriptomic analysis of
ex vivo bone marrow-resident tumor cells (BMRTC) versus CTC identified protein ubiquitination as a significant regulatory pathway of BMRTC signaling. Selective inhibition of USP7, a key deubiquinating enzyme, arrested BMRTCs in bone marrow locales and decreased systemic micrometastasis. This study provides first-time evidence that the asymptomatic progression of metastatic melanoma can be recapitulated
in vivo using patient-isolated CTCs. Furthermore, these results suggest that USP7 inhibitors warrant further investigation as a strategy to prevent progression to overt clinical metastasis.
Significance: These findings provide insights into mechanism of melanoma recurrence and propose a novel approach to inhibit systematic metastatic disease by targeting bone marrow-resident tumor cells through pharmacological inhibition of USP7.
Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/18/5349/F1.large.jpg
Cancer Res; 78(18); 5349-62. ©2018 AACR.
AB - Systemic metastasis is the major cause of death from melanoma, the most lethal form of skin cancer. Although most patients with melanoma exhibit a substantial gap between onset of primary and metastatic tumors, signaling mechanisms implicated in the period of metastatic latency remain unclear. We hypothesized that melanoma circulating tumor cells (CTC) home to and reside in the bone marrow during the asymptomatic phase of disease progression. Using a strategy to deplete normal cell lineages (Lin
-), we isolated CTC-enriched cell populations from the blood of patients with metastatic melanoma, verified by the presence of putative CTCs characterized by melanoma-specific biomarkers and upregulated gene transcripts involved in cell survival and prodevelopment functions. Implantation of Lin
- population in NSG mice (CTC-derived xenografts, i.e., CDX), and subsequent transcriptomic analysis of
ex vivo bone marrow-resident tumor cells (BMRTC) versus CTC identified protein ubiquitination as a significant regulatory pathway of BMRTC signaling. Selective inhibition of USP7, a key deubiquinating enzyme, arrested BMRTCs in bone marrow locales and decreased systemic micrometastasis. This study provides first-time evidence that the asymptomatic progression of metastatic melanoma can be recapitulated
in vivo using patient-isolated CTCs. Furthermore, these results suggest that USP7 inhibitors warrant further investigation as a strategy to prevent progression to overt clinical metastasis.
Significance: These findings provide insights into mechanism of melanoma recurrence and propose a novel approach to inhibit systematic metastatic disease by targeting bone marrow-resident tumor cells through pharmacological inhibition of USP7.
Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/18/5349/F1.large.jpg
Cancer Res; 78(18); 5349-62. ©2018 AACR.
UR - http://www.scopus.com/inward/record.url?scp=85053212575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053212575&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-18-0644
DO - 10.1158/0008-5472.CAN-18-0644
M3 - Article
C2 - 30026332
AN - SCOPUS:85053212575
SN - 0008-5472
VL - 78
SP - 5349
EP - 5362
JO - Cancer research
JF - Cancer research
IS - 18
ER -